| Previous close | 3.2000 |
| Open | 3.6300 |
| Bid | 2.1700 |
| Ask | 4.9500 |
| Strike | 127.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.6500 - 3.6300 |
| Contract range | N/A |
| Volume | |
| Open interest | 228 |
Business WireUSDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
RAHWAY, N.J., June 25, 2024--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Department of Agriculture (USDA) approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of canine influenza. The product is expected to be available at veterinary clinics and hospitals nationwide late this summer.
ZacksMerck (MRK) Increases Despite Market Slip: Here's What You Need to Know
Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session.
Insider MonkeyIs Merck & Co., Inc. (MRK) a Strong Buy Right Now?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other healthcare stocks. You can also check out the 20 Most Valuable Healthcare Companies in the World here. Healthcare […]
